Skip to main content

Table 5 Median and range for PSQI by treatment, with p-value and standardized effect size, d

From: Results of a randomized, double blind, placebo controlled, crossover trial of melatonin for treatment of Nocturia in adults with multiple sclerosis (MeNiMS)

Measure Treatment
A: Placebo B: Melatonin p D
Median Range Median Range
Overall Score 9.0 2–13 8.0 2–16 0.893 0.036
Sleep Disturbances 2.0 1–3 2.0 1–3 0.092 0.471
Sleep Medication 0.0 0–0 0.0 0–3 0.228 0.333
Sleep Duration 1.0 0–3 1.0 0–3 0.663 0.119
Sleep Latency 1.0 0–5 1.0 0–3 0.927 0.025
Sleep Quality 1.0 0–3 1.0 0–3 0.922 0.027
Daytime Dysfunction 1.0 0–3 1.0 1–3 0.141 0.410
Habitual Sleep Efficiency 2.0 0–3 1.0 0–3 0.114 0.440